Levofloxacin Injection, Solution
Product Images NDC 44567-435

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Levofloxacin (NDC 44567-435). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wg Critical Care, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levofloxacin 500 mg Bag Label (Image 01)

Levofloxacin Injection 250 mg (5 mg/mL) in 5% Dextrose solution, 50 mL vial for intravenous use. The label highlights the infusion instructions, storage guidelines, and manufacturer information, WG Critical Care, LLC, made in Switzerland. It specifies single-dose use and contains dilution and pH details.*

FDA Label Image

Levofloxacin 750 mg Bag Label (Image 02)

Levofloxacin Injection 5 mg/mL in 5% Dextrose solution for intravenous use. The label states 500 mg in 100 mL 5% Dextrose with usage instructions to infuse over 60 minutes and cautions about container and dilution. Manufactured by WG Critical Care, LLC, Paramus, NJ, made in Switzerland. The product is sterile and nonpyrogenic.*

FDA Label Image

Image 03

Levofloxacin 750 mg (5 mg/mL) intravenous injection in 5% dextrose, labeled for a 150 mL single-dose container. The label instructs infusion over 90 minutes with no further dilution necessary and notes specific storage and usage precautions. Manufactured by WG Critical Care, LLC.*

FDA Label Image

Chemical Structure (Lev0b 0000 01)

Chemical structure of Levofloxacin, showing its molecular framework including ring systems and functional groups, with a hydrate notation (1/2 H2O) indicated.*

FDA Label Image

Figure 2 (Lev0b 0000 02)

A line graph comparing plasma concentration (µg/mL) over time (hours) for 750 mg Levofloxacin administered orally as a tablet and intravenously via a 90-minute infusion. The plot shows initial plasma concentration peaks and subsequent decline for both administration routes over 36 hours.*

FDA Label Image

Figure 3 (Lev0b 0000 03)

A line graph comparing plasma concentration of levofloxacin over time in micrograms per milliliter (µg/mL) following two administration routes: 500 mg tablet taken orally and 500 mg injection administered intravenously. The x-axis represents time in hours (h) up to 36 hours, and the y-axis represents plasma concentration from 0 to 8 µg/mL. The graph shows both routes reaching similar concentration profiles over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.